The COVID pandemic ushered mRNA vaccines into the spotlight, and the technology has even greater potential. Here’s what to ...

The first human Lyme disease vaccine was 73% effective against the tick-borne illness, says Pfizer. They still plan to seek ...

In 2021, a global tuberculosis vaccine research and development roadmap proposed a series of actions to accelerate the development of new, effective, and affordable vaccines that are urgently needed ...

Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its ...

Cancer is the second-leading cause of death in the United States, accounting for over 613,000 fatalities in 2023, per the ...

The field of cancer immunology has seen significant advancements in recent years, particularly with the emergence of immunotherapy as a key pillar in the ...

Earlier this month, Health Secretary Robert F. Kennedy Jr. announced he’s cutting nearly $500 million in funding for mRNA vaccine development from the Biomedical Advanced Research and Development ...

AAA Biotech’s Validated Antibodies, Recombinant Proteins, and ELISA Kits Power Breakthrough Research Across Drug ...

The field of antivirals and vaccines is pivotal to modern biomedical research, especially in the context of persistent and emerging viral threats. Recent ...

Dengue, a mosquito-borne disease, affects millions of people every year across Asia, Africa and Latin America. And it's ...

The multivalent candidate, being developed by Pfizer and French partner Valneva under a 2020 pact, generated higher than 73% ...